Amy Erbe-Gurel, PhD

September 8, 2021

Neuroblastoma (NBL) is a type of childhood cancer afflicting roughly 800 children annually in the U.S. Patients with high-risk NBL are treated with a regimen that includes immunotherapy that binds to a marker that is present on both tumor cells and some nervous tissue. The binding of this immunotherapy to nervous tissue makes treatment extremely […]

Read More

Delfim Duarte, MD PhD

September 8, 2021

Acute myeloid leukemia (AML) accounts for about 20% of pediatric leukemias and is surpassing acute lymphoblastic leukemia (ALL) as the leading cause of death in children with leukemia. A major concern in a subgroup of AML patients is the persistence of minimal/measurable residual disease (MRD), which is composed by chemoresistant leukemic cells and is associated […]

Read More

Lai Man (Natalie) Wu , PhD

August 11, 2020

Neurofibromatosis type I (NF1), an inherited condition in children, affects one in every 3,000 individuals worldwide. Although benign in nature, in some cases, the slowly growing NF1-mutated nerve tumors can become malignant peripheral nerve sheath tumors (MPNST), killing 50% of the patients within five years. Dr. Wu’s Powered by Pablove research projects aim to unravel […]

Read More

Thais Armangue, MD, PhD

August 11, 2020

All the way in Barcelona, Spain, Dr. Thais Armangue is studying a rare autoimmune condition called Opsoclonus-myoclonus Syndrome (OMS). With her Powered by Pablove funds, Dr. Armangue is using novel technical approaches to identify the specific antibodies involved in OMS, paving the way for a more thorough understanding of how the disease develops.    In […]

Read More